doi:10.3969/j.issn.1004-583X.2025.11.011

Abstract

CLC Number:

R734.2

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2025.11.011

https://www.lchc.cn/EN/Y2025/V40/I11/1031

References 43

[1]	王策. 肺癌连续十年位居癌症死亡率首位[N]. 环球时报, 2025-04-16(004).doi:10.28378/n.cnki.nhqsb.2025.002156.
[2]	付瑞瑛. 中国-大型城市地区和美国人群总体癌症和20种癌症生存率比较[D]. 北京: 北京协和医学院, 2023.doi:10.27648/d.cnki.gzxhu.2023.000981.
[3]	王丽, 冯倩倩, 刘慧, 等. PHGDH介导的代谢重编程在胃癌细胞奥沙利铂耐药中的作用及临床预后价值[J]. 同济大学学报(医学版), 2025, 46(3):333-346.
[4]	徐红, 糜跃萍, 蔡波, 等. 2010-2019年江苏省南通市归因于吸烟的癌症死亡负担研究[J]. 中国肿瘤, 2023, 32(11):813-819.
[5]	Brüske-Hohlfeld I. Environmental and occupational risk factors for lung cancer[J]. Methods Mol Biol, 2009, 472:3-23. doi: 10.1007/978-1-60327-492-0_1. pmid: 19107427
[6]	肖悦, 郑萍, 许宁, 等. 空气污染混合暴露与相对端粒长度对非吸烟女性肺癌的影响研究[J]. 环境卫生学杂志, 2024, 14(4):286-294.doi:10.13421/j.cnki.hjwsxzz.2024.04.002.
[7]	Zeng Q, Vogtmann E, Jia MM, et al. Tobacco smoking and trends in histological subtypes of female lung cancer at the Cancer Hospital of the Chinese Academy of Medical Sciences over 13 years[J]. Thorac Cancer, 2019, 10(8):1717-1724. doi:10.1111/1759-7714.13141.
[8]	Ren Y, Wang M, Yuan H, et al. A novel insight into cancer therapy: Lipid metabolism in tumor-associated macrophages[J]. Int Immunopharmacol, 2024, 135:112319. doi:10.1016/j.intimp.2024.112319.
[9]	Kitahara CM, Berrington de González A, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea[J]. J Clin Oncol, 2011, 29(12):1592-1598. doi: 10.1200/JCO.2010.31.5200. Epub 2011 Mar 21. pmid: 21422422
[10]	Michelet X, Dyck L, Hogan A, et al. Metabolic reprogramming of natural killer cells in obesity limits antitumor responses[J]. Nat Immunol, 2018, 19(12):1330-1340. doi:10.1038/s41590-018-0251-7. pmid: 30420624
[11]	Zhou T, Zhan J, Fang W, et al. Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC)[J]. BMC Cancer, 2017, 17(1):269. doi: 10.1186/s12885-017-3239-z. pmid: 28410578
[12]	秦文昊. 高胆固醇对肿瘤发生发展的作用及机制研究[D]. 上海: 中国人民解放军海军军医大学, 2018.
[13]	王晨曦. 血脂代谢在非小细胞肺癌不同分期时的关系研究[D]. 天津: 天津医科大学, 2021.doi:10.27366/d.cnki.gtyku.2021.000276.
[14]	Umeki S. Decreases in serum cholesterol levels in advanced lung cancer[J]. Respiration, 1993, 60(3):178-181. doi:10.1159/000196195. pmid: 8210722
[15]	Klag MJ, Ford DE, Mead LA, et al. Serum cholesterol in young men and subsequent cardiovascular disease[J]. N Engl J Med, 1993, 328(5):313-318. doi:10.1056/NEJM199302043280504.
[16]	张方. 非小细胞肺癌患者血脂水平的检测及其临床意义[D]. 济南: 山东大学, 2019.
[17]	赵超. 血脂谱与肺癌风险之间的独立相关性[D]. 济南: 山东大学, 2021.doi:10.27272/d.cnki.gshdu.2021.006868.
[18]	Ulmer H, Borena W, Rapp K, et al. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria[J]. Br J Cancer, 2009, 101(7):1202-1206. doi:10.1038/sj.bjc.6605264.
[19]	Lyu Z, Li N, Wang G, et al. Independent and joint associations of blood lipids and lipoproteins with lung cancer risk in Chinese males: A prospective cohort study[J]. Int J Cancer, 2019, 144(12):2972-2984. doi:10.1002/ijc.32051. pmid: 30536993
[20]	Huang YQ, Liu XC, Lo K, et al. The U shaped relationship between high-density lipoprotein cholesterol and all-cause or cause-specific mortality in adult population[J]. Clin Interv Aging, 2020, 15:1883-1896. doi:10.2147/CIA.S271528.
[21]	Liang B, Qiu X, Huang J, et al. Nonlinear associations of the hs-CRP/HDL-C index with metabolic dysfunction-associated steatotic liver disease and advanced liver fibrosis in US adults: Insights from NHANES 2017-2018[J]. Sci Rep, 2025, 15(1):4029.doi:10.1038/s41598-025-88685-y.
[22]	Touvier M, Fassier P, His M, et al. Cholesterol and breast cancer risk: A systematic review and meta-analysis of prospective studies[J]. Br J Nutr, 2015, 114(3):347-357. doi:10.1017/S000711451500183X.
[23]	寇艳婷, 朱星星, 李莉, 等. ABCG1介导的胆固醇外流在SLE患者中的作用及机制研究[J]. 国际检验医学杂志, 2023, 44(1):24-28.
[24]	Zhang T, Wang Q, Wang Y, et al. AIBP and APOA-I synergistically inhibit intestinal tumor growth and metastasis by promoting cholesterol efflux[J]. J Transl Med, 2019, 17(1):161. doi:10.1186/s12967-019-1910-7. pmid: 31101050
[25]	West J, Garg A. Complex dyslipidemia induced by lorlatinib therapy: A case study[J]. J Clin Lipidol, 2025, 19(1):178-182. doi:10.1016/j.jacl.2024.10.003.
[26]	周建明, 黄波, 俸家富. 脂类及脂蛋白在胃肠道癌患者中的作用[J]. 现代医药卫生, 2006, (5):645-646.
[27]	解宝泉, 王红阳, 王袁, 等. 老年肺癌患者血清低密度脂蛋白与CYFRA21-1水平及其相关性分析[J]. 中国临床研究, 2017, 30(1):23-26.doi:10.13429/j.cnki.cjcr.2017.01.006.
[28]	Zhou T, Zhan J, Fang W, et al. Serum low-density lipoprotein and low-density lipoprotein expression levels at diagnosis are favourable prognostic factors for patients with small cell lung cancer (SCLC)[J]. BMC Cancer, 2017, 17:269.doi: 10.1186/s12885-017-3239-z.
[29]	Li Z, Xu J, Feng W, et al. The clinical significance of preoperative serum triglyceride, high-density lipoprotein, and low-density lipoprotein levels in lung squamous cell carcinoma[J]. Sci Rep, 2022, 12(1):16828. doi:10.1038/s41598-022-18589-8. pmid: 36207435
[30]	Qiu J, Zhao Z, Suo H, et al. Linoleic acid exhibits anti-proliferative and anti-invasive activities in endometrial cancer cells and a transgenic model of endometrial cancer[J]. Cancer Biol Ther, 2024, 25(1):2325130. doi:10.1080/15384047.2024.2325130.
[31]	高艳红, 张妍, 田亚平, 等. 不同类型肿瘤患者的血脂水平分析[J]. 标记免疫分析与临床, 2010, 17(5):277-280.doi:CNKI:SUN:BJMY.0.2010-05-004.
[32]	米鲜艳, 谭树芬, 李树清. 不同类型癌症患者血脂改变及其临床意义的探讨[C]// 中国病理生理学会.中国病理生理学会第九届全国代表大会及学术会议论文摘要.云南省血液中心;昆明医学院第三附属医院;昆明医学院; 2010:91.
[33]	Kuhajda FP, Pizer ES, Li JN, et al. Synthesis and antitumor activity of an inhibitor of fatty acid synthase[J]. Proc Natl Acad Sci U S A, 2000, 97(7):3450-3454. doi:10.1073/pnas.97.7.3450.
[34]	Wang J, Xu LF, Liu C, et al. Identifying the role of apolipoprotein A-I in prostate cancer[J]. Asian J Androl, 2021, 23(4):400-408. doi:10.4103/aja.aja_92_20. pmid: 33586698
[35]	Kuliszkiewicz-Janus M, Małecki R, Mohamed AS. Lipid changes occuring in the course of hematological cancers[J]. Cell Mol Biol Lett, 2008, 13(3):465-474. doi:10.2478/s11658-008-0014-9. pmid: 18463797
[36]	Breslow JL, Eisenberg S, Brinton EA. Metabolic determinants of low HDL-C levels[J]. Ann N Y Acad Sci, 1993, 676:157-162. doi:10.1111/j.1749-6632.1993.tb38731.x.
[37]	Mooberry LK, Sabnis NA, Panchoo M, et al. Targeting the SR-B1 receptor as a gateway for cancer therapy and imaging[J]. Front Pharmacol, 2016, 7:466. doi:10.3389/fphar.2016.00466. pmid: 28018216
[38]	Kontush A, Lindahl M, Lhomme M, et al. Structure of HDL: Particle subclasses and molecular components[J]. Handb Exp Pharmacol, 2015, 224:3-51. doi:10.1007/978-3-319-09665-0_1. pmid: 25522985
[39]	张羽健, 俞静. 胆固醇代谢及相关脂蛋白与肺癌的发生和发展[J]. 临床与病理杂志, 2022, 42(5):1225-1232.doi:CNKI:SUN:WYSB.0.2022-05-033.
[40]	吴阳, 姚坚, 陈金亮. 基于ox-LDL/LOX-1信号通路探讨脂质代谢紊乱促进肺癌进展中的机制[J]. 实用医学杂志, 2024, 40(1):19-24.doi:CNKI:SUN:SYYZ.0.2024-01-004.
[41]	Go GW, Mani A. Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis[J]. Yale J Biol Med, 2012, 85(1):19-28.
[42]	Guillaumond F, Bidaut G, Ouaissi M, et al. Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma[J]. Proc Natl Acad Sci U S A, 2015, 112(8):2473-2478. doi:10.1073/pnas.1421601112.
[43]	Benn M, Tybjærg-Hansen A, Stender S, et al. Low-density lipoprotein cholesterol and the risk of cancer: A mendelian randomization study[J]. J Natl Cancer Inst, 2011, 103(6):508-519. doi:10.1093/jnci/djr008. pmid: 21285406

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 43

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2025, 40(8): 742-747.
[2]	. [J]. Clinical Focus, 2025, 40(5): 473-476.
[3]	Li Shufan, Wang Yuxiu, Jiang Zhenghua. The correlation between the prognosis of lung adenocarcinoma with acquired resistance to the first-generation EGFR TKI and the T790M mutation [J]. Clinical Focus, 2022, 37(11): 985-991.
[4]	Huang Ping, Liu Hanyun, Li Yuhong. Risk factors of lung cancer with pulmonary embolism:a meta-analysis [J]. Clinical Focus, 2021, 36(12): 1061-1066.
[5]	. [J]. Clinical Focus, 2021, 36(12): 1132-1135.
[6]	Li Guanzhu, Lai Yuan, Zheng Xiaozhuo, Jiang Ran, Wei Ke. Effects of goal-directed fluid therapy on intraoperative balance between oxygen delivery and consumption and postoperative outcomes in thoracic surgery patients: a meta-analysis [J]. Clinical Focus, 2021, 36(8): 677-684.
[7]	Xu Ying, Han Caijuan, Fan Hong, Meng Zerong, Wang Xiaojun, Liu Hua. Relationship between long non-coding RNA overexpression and poor prognostic of small cell lung cancer: a meta-analysis [J]. Clinical Focus, 2021, 36(8): 685-690.
[8]	Wang Ai. Effects of Kangai injection combined with bevacizumab and DP scheme on efficacy and serum tumor markers and prognosis of NSCLC [J]. Clinical Focus, 2021, 36(6): 517-521.
[9]	Yang Ke, Chen Jun. Value of serum NSE, CEA and CA125 levels in diagnosis and efficacy evaluation of patients with small cell lung cancer [J]. Clinical Focus, 2021, 36(3): 225-228.
[10]	Liu Xinyan,Wei Hongyan, Dai Xianli, Liu Ying. Clinical efficacy of chemotherapy combined with location intervened by bronchoscope in central lung cancer [J]. Clinical Focus, 2016, 31(4): 389-391.
[11]	Li Yajie;Chen Kai. Analysis of transbronchial needle aspiration in 224 cases with mediastinal lymphadenectasis [J]. Clinical Focus, 2015, 30(10): 1159-1162.
[12]	. @@ [J]. Clinical Focus, 2015, 30(10): 1197-1200.
[13]	Chi Hongwei;Wang Canghai;Yang Zhiming;Ren Jinjun;Xu Qian;Chen Yanfang. Appilcation of apparent diffusion coefficient value in chemotherapy efficacy evaluation on non-small cell lung carcinoma [J]. Clinical Focus, 2015, 30(8): 883-887.
[14]	Du Junhua;Yin Yifa;Qiao Hongyuan. Effect of maintenance therapy with Huisheng Oral Liquid for patients in mid-advanced non-small cell lung cancer [J]. Clinical Focus, 2015, 30(6): 641-644.
[15]	Hu Shanshan;Zhang Shun;Cai Ting. Immunochemotherapy for advanced non-small cell lung cancer:a meta-analysis [J]. Clinical Focus, 2015, 30(3): 283-289.